Physician profile
Donnell M Proctor
NPI 1720234578
$2,123.31
in general payments reported to CMS, 2019-2025
14 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $480 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $274.51 | 2024-2025 | Carvykti, Rybrevant, Erleada |
| Beone Medicines USA, INC. | $254.40 | 2025 | Tevimbra, Brukinsa |
| Regeneron Healthcare Solutions, INC. | $246.90 | 2024-2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $148.15 | 2025 | Somatuline Depot, Onivyde |
| Legend Biotech USA INC. | $138.54 | 2025 | Carvykti |
| Daiichi Sankyo INC. | $124.74 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.74 | 2025 | |
| Kite Pharma, INC. | $121.84 | 2025 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $120.39 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $119.70 | 2025 | Datroway |
| Gilead Sciences, INC. | $119.70 | 2025 | Trodelvy |
| Recordati_rare_diseases_inc. | $115.50 | 2025 | Sylvant |
| Emd Serono, INC. | $113.40 | 2024 | |
| Genzyme Corporation | $100.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donnell Proctor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.